

Ruthenium(II)-catalyzed remote C-H addition of 8 aminoquinoline amide to activated aldehyde

Susmita Mondal and Alakananda Hajra*

Department of Chemistry, Visva-Bharati (A Central University), Santiniketan 731235, India

Tel./Fax: +913463 261526; E-mail: alakananda.hajra@visva-bharati.ac.in

Table of Contents

Content	Page no.
1. General Information.....	S2
2. Typical experimental procedure for the compound 3a	S2
3. Characterization data for the synthesized compounds (3a-3s and 5a, 5b)	S3-S13
4. References.....	S13
5. Structure Determination (X-ray crystallographic data for 3d):	S13-S14
6. NMR spectra for the synthesized products.....	S15-S57


1. General Information:

All reagents were purchased from commercial sources and used without further purification. ^1H NMR spectra were determined on 400 MHz spectrometer as solutions in CDCl_3 . Chemical shifts were expressed in parts per million (δ) and the signals were reported as s (singlet), br s (broad singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet), m (multiplet), and coupling constants (J) were given in Hz. $^{13}\text{C}\{\text{H}\}$ NMR spectra were recorded at 100 MHz in CDCl_3 solution. Chemical shifts as internal standard were referenced to CDCl_3 ($\delta = 7.26$ for ^1H and $\delta = 77.16$ for $^{13}\text{C}\{\text{H}\}$ NMR) as internal standard. TLC was done on silica gel coated glass slide. All solvents were dried and distilled before use. Commercially available solvents were freshly distilled before the reaction. All reactions involving moisture sensitive reactants were executed using oven dried glassware. All the 8-aminoquinoline amides were prepared by the reported method.^[1]


2. Typical experimental procedure for the compound ethyl 2-(8-benzamidoquinolin-5-yl)-2-hydroxyacetate (3a):

N-(Quinolin-8-yl)benzamide (**1a**) (0.2 mmol, 49.6 mg), ethyl glyoxalate solution (**2a**) (2 equiv., 40.8 mg), $[\text{Ru}(p\text{-Cy})\text{Cl}_2]_2$ (5 mol%, 3.06 mg), AgSbF_6 (10mol%, 6.86 mg), and NaOAc (2 equiv., 32.8 mg) was taken in a reaction tube with cap. Then 1,2-DCE (2 mL) was added to it and stirred at 100°C for 8 h. After completion of the reaction (TLC), the reaction mixture was quenched with water (2 mL). The reaction mixture was then extracted with ethyl acetate. The organic phase was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to get the crude residue which was purified by column chromatography on silica gel (60-120 mesh) using petroleum ether:ethyl acetate = 4:1 as an eluent to afford the pure product (**3a**) (51.8 mg, 74%) as a light yellow gummy mass.


3. Characterization data for the synthesized compounds (3a-3s and 5a, 5b):




Ethyl 2-(8-benzamidoquinolin-5-yl)-2-hydroxyacetate (3a): Light yellow gummy mass (74%, 51.8 mg); $R_f = 0.45$ (PE:EA = 80:20); ^1H NMR (400 MHz, CDCl_3): δ 10.82 (s, 1H), 8.89-8.85 (m, 2H), 8.57 (dd, $J = 8.8$ Hz, 1.6 Hz, 1H), 8.08-8.06 (m, 2H), 7.60-7.50 (m, 5H), 5.68 (s, 1H), 4.28-4.17 (m, 2H), 3.67 (br s, 1H), 1.14 (t, $J = 7.2$ Hz, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 173.9, 165.6, 148.2, 139.1, 135.3, 135.0, 133.1, 132.0, 128.9, 128.2, 127.6, 127.4, 126.2, 121.9, 115.7, 71.5, 62.6, 14.1; Anal. Calcd for $\text{C}_{20}\text{H}_{18}\text{N}_2\text{O}_4$: C, 68.56; H, 5.18; N, 8.00%; Found: C, 68.80; H, 5.11; N, 8.12%.




Ethyl 2-hydroxy-2-(8-(3-methylbenzamido)quinolin-5-yl)acetate (3b): Light yellow gummy mass (76%, 55.4 mg); $R_f = 0.55$ (PE:EA = 75:25); ^1H NMR (400 MHz, CDCl_3): δ 10.77 (s, 1H), 8.88-8.85 (m, 2H), 8.56 (dd, $J = 8.4$ Hz, 1.6 Hz, 1H), 7.87-7.84 (m, 2H), 7.58 (d, $J = 8.0$ Hz, 1H), 7.52-7.49 (m, 1H), 7.44-7.38 (m, 2H), 5.68 (s, 1H), 4.29-4.12 (m, 2H), 3.69 (br s, 1H), 2.47 (s, 3H), 1.14 (t, $J = 7.2$ Hz, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 173.8, 165.9, 148.2, 139.1, 138.8, 135.4, 135.1, 133.1, 132.8, 128.8, 128.2, 127.6, 126.2, 124.3, 121.9, 115.8, 71.5, 62.5, 21.6, 14.1; Anal. Calcd for $\text{C}_{21}\text{H}_{20}\text{N}_2\text{O}_4$: C, 69.22; H, 5.53; N, 7.69%; Found: C, 69.40; H, 5.58; N, 7.77%.




Ethyl 2-hydroxy-2-(8-(4-methylbenzamido)quinolin-5-yl)acetate (3c): White solid (82%, 59.7 mg); $R_f = 0.45$ (PE:EA = 80:20); M.p. 89-90 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.79 (s, 1H), 8.89-8.86 (m, 2H), 8.56 (dd, $J = 8.4$ Hz, 1.6 Hz, 1H), 7.98-7.96 (m, 2H), 7.59 (d, $J = 8.0$ Hz, 1H), 7.53-7.50 (m, 1H), 7.34 (d, $J = 8.0$ Hz, 2H), 5.68 (s, 1H), 4.28-4.14 (m, 2H), 3.60 (br s, 1H), 2.45 (s, 3H), 1.14 (t, $J = 7.2$ Hz, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 173.9, 165.6, 148.2, 142.6, 139.2, 135.5, 133.1, 132.3, 129.6, 128.0, 127.7, 127.4, 126.2, 121.9, 115.7, 71.5, 62.6, 21.6, 14.1; Anal. Calcd for $\text{C}_{21}\text{H}_{20}\text{N}_2\text{O}_4$: C, 69.22; H, 5.53; N, 7.69%; Found: C, 69.01; H, 5.61; N, 7.60%.




Ethyl 2-hydroxy-2-(8-(4-methoxybenzamido)quinolin-5-yl)acetate (3d): White solid (78%, 59.4 mg); $R_f = 0.50$ (PE:EA = 70:30); M.p. 85-86 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.70 (s, 1H), 8.83-8.78 (m, 2H), 8.55 (dd, $J = 8.8$ Hz, 1.2 Hz, 1H), 8.03-7.99 (m, 2H), 7.54 (d, $J = 8.0$ Hz, 1H), 7.49-7.45 (m, 1H), 7.02-6.99 (m, 2H), 5.66 (s, 1H), 4.27-4.10 (m, 2H), 3.87 (s, 4H), 1.12 (t, $J = 7.2$ Hz, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 173.7, 165.1, 162.6, 148.1, 139.0, 135.4, 133.2, 129.2, 128.0, 127.5, 127.2, 126.1, 121.8, 115.5, 114.1, 71.5, 62.4, 55.5, 14.0; HRMS (ESI-TOF) m/z : [M + H]⁺Calcd for $\text{C}_{21}\text{H}_{20}\text{N}_2\text{O}_5$: 381.1445; found: 381.1449.




Ethyl 2-(8-(4-fluorobenzamido)quinolin-5-yl)-2-hydroxyacetate (3e): White solid (68%, 50.0 mg); R_f = 0.55 (PE:EA = 75:25); M.p 102-103 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.77 (s, 1H), 8.87-8.84 (m, 2H), 8.57 (dd, J = 8.4 Hz, 1.6 Hz, 1H), 8.10-8.06 (m, 2H), 7.60 (d, J = 8.0 Hz, 1H), 7.54-7.51 (m, 1H), 7.24-7.20 (m, 2H), 5.64 (s, 1H), 4.26-4.16 (m, 2H), 3.64 (br s, 1H), 1.14 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 173.9, 164.5, 148.2, 139.1, 134.2 (J_{C-F} = 200.0 Hz), 131.3 (J_{C-F} = 4.0 Hz), 129.89, 129.81, 128.3, 127.6, 126.2, 122.0, 116.1, 115.9, 115.8, 71.5, 62.6, 14.1; Anal. Calcd for C₂₀H₁₇FN₂O₄: C, 65.21; H, 4.65; N, 7.60%; Found: C, 65.05; H, 4.59; N, 7.51%.




Ethyl 2-(8-(3-chlorobenzamido)quinolin-5-yl)-2-hydroxyacetate (3f): White solid (72%, 55.3 mg); R_f = 0.55 (PE:EA = 80:20); M.p. 94-95 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.76 (s, 1H), 8.87 (dd, J = 4.4 Hz, 1.6 Hz, 1H), 8.83 (d, J = 8.0 Hz, 1H), 8.57 (dd, J = 8.8 Hz, 1.6 Hz, 1H), 8.04 (t, J = 2.0 Hz, 1H), 7.94-7.91 (m, 1H), 7.60-7.46 (m, 4H), 5.68 (d, J = 3.2 Hz, 1H), 4.27-4.14 (m, 2H), 3.70 (d, J = 4.0 Hz, 1H), 1.14 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 173.8, 164.1, 148.3, 139.0, 136.8, 135.1, 135.0, 133.2, 132.1, 130.2, 128.6, 127.8, 127.5, 126.2, 125.4, 122.0, 115.9, 71.4, 62.6, 14.1; Anal. Calcd for C₂₀H₁₇ClN₂O₄: C, 62.42; H, 4.45; N, 7.28%; Found: C, 62.25; H, 4.55; N, 7.39%.




Ethyl 2-(8-(4-chlorobenzamido)quinolin-5-yl)-2-hydroxyacetate (3g): White solid (76%, 58.4 mg); R_f = 0.50 (PE:EA = 75:25); M.p. 131-132 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.77 (s, 1H), 8.86-8.82 (m, 2H), 8.57 (dd, J = 8.8 Hz, 1.6 Hz, 1H), 8.01-7.98 (m, 2H), 7.58 (d, J = 8.0 Hz, 1H), 7.53-7.49 (m, 3H), 5.67 (d, J = 3.6 Hz, 1H), 4.27-4.14 (m, 2H), 3.69 (d, J = 4.4 Hz, 1H), 1.14 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 173.8, 164.5, 148.2, 139.0, 138.3, 135.1, 133.4, 133.2, 129.2, 128.8, 128.5, 127.5, 126.2, 122.0, 115.8, 71.5, 62.6, 14.1; Anal. Calcd for C₂₀H₁₇ClN₂O₄: C, 62.42; H, 4.45; N, 7.28%; Found: C, 62.60; H, 4.49; N, 7.19%.




Ethyl 2-(8-(2-bromobenzamido)quinolin-5-yl)-2-hydroxyacetate (3h): Yellow gummy mass (65%, 55.8 mg); R_f = 0.45 (PE:EA = 80:20); ¹H NMR (400 MHz, CDCl₃): δ 10.86 (s, 1H), 8.93 (d, J = 8.0 Hz, 1H), 8.89 (dd, J = 4.4 Hz, 1.6 Hz, 1H), 8.64 (dd, J = 8.8 Hz, 1.6 Hz, 1H), 8.09-8.07 (m, 2H), 7.72 (d, J = 8.4 Hz, 1H), 7.60-7.56 (m, 3H), 6.52 (s, 1H), 4.26-4.11 (m, 2H), 1.15 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 170.4, 169.0, 165.7, 148.4, 139.0, 136.0, 135.0, 134.4, 133.3, 132.1, 129.2, 129.0, 127.4, 126.3, 124.1, 122.3, 115.8, 72.6, 62.1, 14.1; Anal. Calcd for C₂₀H₁₇BrN₂O₄: C, 55.96; H, 3.99; N, 6.53%; Found: C, 55.81; H, 3.93; N, 6.63%.




Ethyl 2-(8-(4-bromobenzamido)quinolin-5-yl)-2-hydroxyacetate (3i): Yellow solid (70%, 60.1 mg); $R_f = 0.50$ (PE:EA = 80:20); M.p. 134-135 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.79 (s, 1H), 8.87-8.84 (m, 2H), 8.57 (dd, J = 8.8 Hz, 1.6 Hz, 1H), 7.95-7.92 (m, 2H), 7.70-7.67 (m, 2H), 7.60 (d, J = 8.0 Hz, 1H), 7.55-7.51 (m, 1H), 5.68 (d, J = 3.6 Hz, 1H), 4.30-4.13 (m, 2H), 3.60 (d, J = 4.0 Hz, 1H), 1.14 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 173.8, 164.6, 148.3, 139.1, 135.1, 133.9, 133.2, 132.2, 129.0, 128.5, 127.6, 126.8, 126.2, 122.0, 115.9, 71.5, 62.6, 14.1; Anal. Calcd for C₂₀H₁₇BrN₂O₄: C, 55.96; H, 3.99; N, 6.53%; Found: C, 56.14; H, 4.06; N, 6.41%.



Ethyl 2-hydroxy-2-(8-(4-iodobenzamido)quinolin-5-yl)acetate (3j): White solid (72%, 68.7 mg); $R_f = 0.50$ (PE:EA = 70:30); M.p. 155-156 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.77 (s, 1H), 8.85-8.81 (m, 2H), 8.56 (d, J = 8.4 Hz, 1H), 7.88 (dd, J = 8.4 Hz, 1.6 Hz, 2H), 7.77 (dd, J = 8.4 Hz, 2.0 Hz, 2H), 7.58 (dd, J = 8.0 Hz, 2.8 Hz, 1H), 7.53-7.49 (m, 1H), 5.67 (s, 1H), 4.27-4.12 (m, 2H), 3.70 (d, J = 11.6 Hz, 1H), 1.13 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 173.8, 164.8, 148.2, 139.0, 138.1, 135.0, 134.4, 133.2, 128.9, 128.5, 127.5, 126.2, 122.0, 115.8, 99.2, 71.4, 62.5, 14.0; HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₀H₁₇IN₂O₄: 477.0306; found: 477.0302.




Ethyl 2-hydroxy-2-(8-(3-(trifluoromethyl)benzamido)quinolin-5-yl)acetate (3k): White solid (61%, 51.0 mg); $R_f = 0.55$ (PE:EA = 80:20); M.p. 102-103 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.85 (s, 1H), 8.88-8.85 (m, 2H), 8.58 (dd, $J = 8.8$ Hz, 1.6 Hz, 1H), 8.33 (s, 1H), 8.23 (d, $J = 7.6$ Hz, 1H), 7.84 (d, $J = 8.0$ Hz, 1H), 7.69 (t, $J = 8.0$ Hz, 1H), 7.61 (d, $J = 8.4$ Hz, 1H), 7.55-7.52 (m, 1H), 5.69 (s, 1H), 4.30-4.13 (m, 2H), 3.66 (br s, 1H), 1.14 (t, $J = 7.2$ Hz, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 173.8, 164.1, 148.4, 139.1, 135.9, 134.9, 133.3, 131.7, 131.4, 130.4, 129.5, 128.7, 128.6 ($J_{\text{C}-\text{F}} = 8.0$ Hz, 5.0 Hz), 127.5, 126.2, 124.7 ($J_{\text{C}-\text{F}} = 8.0$ Hz, 5.0 Hz), 122.1, 116.0, 71.4, 62.6, 14.1; Anal. Calcd for $\text{C}_{21}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_4$: C, 60.29; H, 4.10; N, 6.70%; Found: C, 60.48; H, 4.18; N, 6.61%.




Ethyl 2-(8-([1,1'-biphenyl]-4-carboxamido)quinolin-5-yl)-2-hydroxyacetate (3l): White solid (77%, 65.6 mg); $R_f = 0.45$ (PE:EA = 75:25); M.p. 92-93 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.87 (s, 1H), 8.91-8.88 (m, 2H), 8.58 (dd, $J = 8.8$ Hz, 1.6 Hz, 1H), 8.16-8.14 (m, 2H), 7.79-7.76 (m, 2H), 7.67-7.65 (m, 2H), 7.61 (d, $J = 8.0$ Hz, 1H), 7.55-7.47 (m, 3H), 7.43-7.39 (m, 1H), 5.69 (s, 1H), 4.29-4.15 (m, 2H), 3.65 (br s, 1H), 1.15 (t, $J = 7.2$ Hz, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 173.9, 165.3, 148.2, 144.8, 140.1, 139.1, 135.4, 133.7, 133.2, 129.1, 128.2, 127.9,

127.7, 127.6, 127.3, 126.2, 122.0, 115.8, 71.5, 62.6, 14.1; Anal. Calcd for C₂₆H₂₂N₂O₄: C, 73.23; H, 5.20; N, 6.57%; Found: C, 73.39; H, 5.13; N, 6.46%.




Ethyl 2-(furan-2-carboxamido)quinolin-5-yl)-2-hydroxyacetate (3m): White solid (79%, 53.7 mg); R_f = 0.45 (PE:EA = 80:20); M.p. 112-113 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.84 (s, 1H), 8.90 (dd, J = 4.0 Hz, 1.6 Hz, 1H), 8.82 (d, J = 8.0 Hz, 1H), 8.56 (dd, J = 8.8 Hz, 1.6 Hz, 1H), 7.63 (t, J = 1.2 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.54-7.51 (m, 1H), 7.30 (d, J = 3.6 Hz, 1H), 6.59 (dd, J = 3.6 Hz, 1.6 Hz, 1H), 5.68 (d, J = 3.2 Hz, 1H), 4.28-7.14 (m, 2H), 3.60 (d, J = 4.0 Hz, 1H), 1.14 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 173.9, 156.5, 148.3, 144.7, 139.0, 135.0, 133.1, 128.3, 127.5, 126.2, 122.0, 115.9, 115.4, 112.6, 71.5, 62.6, 14.1; Anal. Calcd for C₁₈H₁₆N₂O₅: C, 63.53; H, 4.74; N, 8.23%; Found: C, 63.32; H, 4.79; N, 8.31%.




Ethyl 2-(cyclohexanecarboxamido)quinolin-5-yl)-2-hydroxyacetate (3n): White solid (72%, 51.3 mg); R_f = 0.55 (PE:EA = 80:20); M.p. 153-154 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.96 (s, 1H), 8.81 (dd, J = 4.0 Hz, 1.6 Hz, 1H), 8.73 (d, J = 8.0 Hz, 1H), 8.53 (dd, J = 8.4 Hz, 1.6 Hz, 2H), 7.53-7.47 (m, 2H), 5.64 (s, 1H), 4.25-4.12 (m, 1H), 3.66 (br s, 1H), 2.49-2.42 (m, 1H), 2.08-2.04 (m, 2H), 1.88-1.84 (m, 2H), 1.74-1.70 (m, 1H), 1.66-1.56 (m, 2H), 1.42-1.26 (m, 3H), 1.12 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): 175.1, 173.9, 148.0, 138.8, 135.4,

133.1, 127.8, 127.6, 126.1, 121.8, 115.6, 71.5, 62.5, 47.0, 29.8, 25.8, 14.0; Anal. Calcd for C₂₀H₂₄N₂O₄: C, 67.40; H, 6.79; N, 7.86%; Found: C, 67.63; H, 6.87; N, 7.72%.




Ethyl 2-(8-acetamidoquinolin-5-yl)-2-hydroxyacetate (3o): White solid (74%, 42.6 mg); R_f = 0.45 (PE:EA = 75:25); M.p. 191-192 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.86 (s, 1H), 8.81 (dd, J = 4.0 Hz, 1.6 Hz, 1H), 8.71 (d, J = 8.0 Hz, 1H), 8.54 (dd, J = 8.8 Hz, 1.6 Hz, 1H), 7.54-7.48 (m, 2H), 5.65 (s, 1H), 4.26-4.11 (m, 2H), 2.34 (s, 3H), 3.58 (br s, 1H), 1.13 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 173.8, 168.9, 147.9, 138.5, 135.2, 133.0, 127.8, 127.5, 126.0, 121.7, 115.5, 71.3, 62.4, 25.1, 13.9; Anal. Calcd for C₁₅H₁₆N₂O₄: C, 62.49; H, 5.59; N, 9.72%; Found: C, 62.30; H, 5.63; N, 9.81%.




Ethyl 2-(8-butyramidoquinolin-5-yl)-2-hydroxyacetate (3p): Yellow gummy mass (79%, 49.9 mg); R_f = 0.55 (PE:EA = 70:30); ¹H NMR (400 MHz, CDCl₃): δ 9.89 (s, 1H), 8.81 (dd, J = 4.0 Hz, 1.6 Hz, 1H), 8.74 (d, J = 8.4 Hz, 1H), 8.53 (dd, J = 8.8 Hz, 1.6 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.51-7.48 (m, 1H), 5.65 (s, 1H), 4.26-4.13 (m, 2H), 3.55 (br s, 1H), 2.54 (t, J = 7.6 Hz, 2H), 1.89-1.80 (m, 2H), 1.13 (t, J = 7.2 Hz, 3H), 1.05 (t, J = 7.6 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 173.9, 172.0, 148.0, 138.7, 135.4, 133.1, 127.8, 127.7, 126.1, 121.8, 115.6, 71.5, 62.6,

40.3, 19.2, 14.1, 13.9; Anal. Calcd for C₁₇H₂₀N₂O₄: C, 64.54; H, 6.37; N, 8.86%; Found: C, 64.36; H, 6.43; N, 8.75%.




Ethyl 2-hydroxy-2-(8-pivalamidoquinolin-5-yl)acetate (3q): Yellow gummy mass (80%, 52.8 mg); R_f = 0.50 (PE:EA = 75:25); ¹H NMR (400 MHz, CDCl₃): δ 10.35 (s, 1H), 8.82 (dd, J = 4.4 Hz, 1.6 Hz, 1H), 8.74 (d, J = 8.0 Hz, 1H), 8.53 (dd, J = 8.8 Hz, 1.6 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.50-7.47 (m, 1H), 5.64 (s, 1H), 4.25-4.14 (m, 2H), 3.55 (br s, 1H), 1.41 (s, 9H), 1.12 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 177.5, 173.9, 148.1, 139.1, 135.5, 133.0, 127.74, 127.70, 126.1, 121.8, 115.4, 71.5, 62.5, 40.5, 27.8, 14.0; Anal. Calcd for C₁₈H₂₂N₂O₄: C, 65.44; H, 6.71; N, 8.48%; Found: C, 65.59; H, 6.67; N, 8.40%.




4-Methyl-N-(5-(2,2,2-trifluoro-1-hydroxyethyl)quinolin-8-yl)benzamide (3r): White solid (61%, 43.9 mg); R_f = 0.50 (PE:EA = 80:20); M.p. 178-179 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.71 (s, 1H), 8.82 (dd, J = 4.4 Hz, 1.6 Hz, 1H), 8.75 (d, J = 8.0 Hz, 1H), 8.50 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.0 Hz, 1H), 7.48-7.44 (m, 1H), 7.34 (d, J = 8.0 Hz, 2H), 5.63 (q, J = 6.8, 1H), 3.82 (br s, 1H), 2.46 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 165.8, 148.2, 142.9, 138.6, 135.7, 132.9, 131.9, 129.7, 128.2, 127.4, 126.2 (J_{C-F} = 22.0 Hz),

124.1, 123.3, 122.0, 115.6, 70.4 ($J_{C-F} = 66.0$ Hz, 33.0 Hz), 21.7 ; Anal. Calcd for $C_{19}H_{15}F_3N_2O_2$: C, 63.33; H, 4.20; N, 7.77%; Found: C, 63.54; H, 4.26; N, 7.89%.




N-(5-(2,2,2-trifluoro-1-hydroxyethyl)quinolin-8-yl)cyclohexanecarboxamide (3s): White solid (69%, 48.6 mg); $R_f = 0.55$ (PE:EA = 80:20); M.p. 142-1432 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.98 (s, 1H), 8.81 (dd, $J = 4.4$ Hz, 1.6 Hz, 1H), 8.68 (d, $J = 8.0$ Hz, 1H), 8.55 (d, $J = 8.4$ Hz, 1H), 7.73 (d, $J = 8.0$ Hz, 1H), 7.52-7.49 (m, 1H), 5.64 (q, $J = 6.8$ Hz, 1H), 3.72 (br s, 1H), 2.48-2.40 (m, 1H), 2.06-2.02 (m, 2H), 1.88-1.84 (m, 2H), 1.74-1.72 (m, 1H), 1.63-1.54 (m, 2H), 1.41-1.29 (m, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 175.4, 148.1, 138.4, 135.8, 132.9, 128.2, 126.2 ($J_{C-F} = 19.0$ Hz), 123.8, 123.3, 121.9, 115.6, 70.4 ($J_{C-F} = 65.0$ Hz, 33.0 Hz), 47.0, 29.8, 29.7, 25.8; Anal. Calcd for $C_{18}H_{19}F_3N_2O_2$: C, 61.36; H, 5.44; N, 7.95%; Found: C, 61.50; H, 5.49; N, 8.02%.



Ethyl 2-(8-benzamido-7-methylquinolin-5-yl)-2-hydroxyacetate (5a): Yellow gummy mass (81%, 59.0 mg); $R_f = 0.50$ (PE:EA = 80:20); ¹H NMR (400 MHz, CDCl₃): δ 9.57 (s, 1H), 8.79 (dd, $J = 4.4$ Hz, 1.6 Hz, 1H), 8.50 (dd, $J = 8.8$ Hz, 1.6 Hz, 1H), 8.09-8.07 (m, 2H), 7.60-7.56 (m, 1H), 7.54-7.50 (m, 3H), 7.43-7.40 (m, 1H), 5.70 (s, 1H), 4.32-4.09 (m, 2H), 3.74 (br s, 1H), 2.52 (s, 3H), 1.16 (t, $J = 7.2$ Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 173.7, 166.0, 148.7, 142.6,

134.6, 133.1, 132.4, 132.1, 130.8, 130.5, 128.8, 128.0, 124.7, 120.9, 71.0, 62.7, 20.6, 14.1; Anal. Calcd for C₂₁H₂₀N₂O₄: C, 69.22; H, 5.53; N, 7.69%; Found: C, 69.01; H, 5.63; N, 7.57%.





Ethyl 2-(8-(4-chlorobenzamido)-7-methylquinolin-5-yl)-2-hydroxyacetate (5b): White solid (75%, 59.7 mg); R_f = 0.50 (PE:EA = 80:20); M.p. 162-163 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.62 (s, 1H), 8.77 (dd, J = 4.4 Hz, 1.6 Hz, 1H), 8.48 (dd, J = 8.4 Hz, 1.6 Hz, 1H), 8.02-7.99 (m, 2H), 7.52 (s, 1H), 7.49-7.45 (m, 2H), 7.42-7.39 (m, 1H), 5.68 (s, 1H), 4.29-4.10 (m, 2H), 3.70 (br s, 1H), 2.50 (s, 3H), 1.15 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 173.7, 164.9, 148.9, 142.8, 138.3, 133.1, 132.8, 132.3, 131.0, 130.4, 129.4, 129.0, 128.7, 124.6, 121.0, 71.0, 62.7, 20.6, 14.1; Anal. Calcd for C₂₁H₁₉ClN₂O₄: C, 63.24; H, 4.80; N, 7.02%; Found: C, 63.09; H, 4.71; N, 7.15%.

4. References:

- [1] a) C. J. Whiteoak, O. Planas, A. Company, X. Ribas, *Adv. Synth. Catal.* **2016**, *358*, 1679;
- b) Y. He, N. Zhao, L. Qiu, X. Zhang, X. Fan, *Org. Lett.* **2016**, *18*, 6054.

5. Structure Determination (X-ray crystallographic data for 3d):

The white crystals of **3d** was obtained by crystallization from a solution in dichloromethane/petroleum ether after purification by column chromatography. Chemical Formula: C₂₁H₂₀N₂O₅.





ORTEP (with 50% probability) diagram for the structure ethyl 2-hydroxy-2-(8-(4-methoxybenzamido)quinolin-5-yl)acetate (**3d**).


Wavelength	0.71073 Å
Formula	C ₂₁ H ₂₀ N ₂ O ₅
Crystal system	Monoclinic
Space group	P 21/n
Unit cell dimensions	a = 8.809(11) Å α = 90° b = 12.652(16) Å β = 91.413(13)° c = 16.37(2) Å γ = 90°
Volume	1824(4) Å ³
Z	4
R-factor (%)	11.41


The crystallographic data have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication with a CCDC reference number CCDC **1831821**.


6. NMR spectra for the synthesized products
























































BRUKER

Current Data Parameters
 NAME Dr.A.HAJRA 2017
 EXPNO 1843
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20171106
 Time_ 20.21
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgpp30
 TD 32768
 SOLVENT CDCl3
 NS 400
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 93.46
 DW 20.800 usec
 DE 6.50 usec
 TS 297.6 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TDD 1

----- CHANNEL f1 -----
 SFO1 100.6278588 MHz
 NUC1 13C
 PI 8.90 usec
 PW1 54.0000000 W

----- CHANNEL f2 -----
 SFO2 400.1516006 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 12.00000000 W
 PLW12 0.32231000 W
 PLW13 0.16212000 W

F2 - Processing parameters
 SI 16384
 SF 100.6177879 MHz
 WM EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.20

